Precision for Medicine Acquires ACT Oncology         
New Century

ACT Oncology (ACT), an oncology-specialist, clinical research organization (CRO), announced today that Patricia Devitt-Risse, Pharm. D, President of the company, has been named a finalist for the Ernst & Young Entrepreneur Of The Year® 2015 Award for the state of New Jersey.  With selection administered by a panel of independent judges, this prestigious awards program recognizes entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance and personal commitment to their respective businesses and communities.


Founded by Dr. Devitt-Risse in 2000 and certified as a Womens Business Enterprise by the State of New Jersey, ACT Oncology is a recognized leader in providing specialized clinical operations services to biotech, pharmaceutical and non-profit oncology organizations throughout the world.  Their reputation for having a strong focus on study quality and experienced, stable project teams have made ACT a sought-after oncology development partner, particularly for complex oncology trials and those in need of rescue.   A testament to their success is their repeat business and employee retention rate of over 95%.

“I am honored to be named a finalist for this prestigious award,” said Dr. Devitt-Risse.  This company was created with a deep and personal commitment to helping cancer patients in need. Today, I am thrilled at the impact ACT Oncology has had in oncology clinical development, through partnerships with our clients. The continued growth and success of this organization can be greatly attributed to its employees, who share the same passion and commitment for oncology clinical development and entrepreneurial spirit, on which ACT was founded.”

Now in its 29th year, the EY Entrepreneur program has expanded to recognize business leaders in more than 145 cities in more than 60 countries throughout the world. 

 The Ernst & Young Entrepreneur Of The Year® 2015 Award will be announced at the annual awards gala in Palm Springs, California, on November 14, 2015. The awards are the culminating event of the EY Strategic Growth Forum®, the nation’s most prestigious gathering of high-growth, market-leading companies.


Founded and produced by EY, the Entrepreneur Of The Year Awards are sponsored nationally by the Ewing Marion Kauffman Foundation and SAP America.  In New Jersey, sponsors also include Cresa, DLA Piper, Empire Valuation Consultants, Merrill Corporation, Morgan Lewis, Murray Devine, NJ BIZ, PNC, Scherzer International, SolomonEdwardsGroup.

 About EY Entrepreneur Of The Year®:

EY Entrepreneur Of The Year is the world’s most prestigious business award for entrepreneurs. The unique award makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, Entrepreneur Of The Year celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 145 cities in more than 60 countries.

 About EY:

 EY is a global leader in assurance, tax, transaction and advisory services. The insights and quality services EY delivers help build trust and confidence in the capital markets and in economies the world over. They develop outstanding leaders who team to deliver on promises to all of its stakeholders. In so doing, EY plays a critical role in building a better working world for its people, its clients and for communities.

 About ACT Oncology:

ACT Oncology is a full-service CRO, specializing in providing outstanding, cost-effective and responsive oncology drug development support for biotech, pharmaceutical and non-profit oncology organizations. Our team of clinical research experts is dedicated to supporting our Sponsors’ Phase I-III oncology programs, registries and Investigator Sponsored Trials for hematologic and solid tumor indications.

Services offered by ACT Oncology include: Study Consultation and Feasibility, Study Start-up, Project Management, Global Trial Implementation and Management, Clinical Monitoring, Site Management, Medical Monitoring, Safety Reporting, Data Management, Clinical Programming, Statistical Analysis and Reporting, Study Quality Metrics and Regulatory and Compliance Consulting

July, 2015

Upcoming Event:

Join us in Boston, July 15-16 at Arena's Clinical Operations in Oncology Trials - East Coast Conference - as Patricia Devitt-Risse, Pharm.D, President and CEO of ACT Oncology speaks on "Strategies for Optimizing Adherence in Oncology Trials: A Focus on What Really Matters."

ACT Oncology invites you to join us in Chicago, May 30-June 1 for the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting.

Please come visit us at Booth #345 in Philadelphia, PA at the 2015 International BIO Convention.  The Exhibit Hall will be open June 16, 17 and 18th.

To set up a personal meeting with an ACT representative, please contact:

Pat Terek at


Chris Ellis at

ACT Oncology is very pleased to announce the promotion of Jeff Seroskie to Corporate Vice President.

Jeff has been instrumental in driving ACT Oncology’s growth and success since he joined the company in 2005. His strong leadership, strategic vision and overall performance have resulted in the award of several important programs.  Jeff’s outstanding operational expertise and steadfast commitment to providing exceptional service continue to drive ACT Oncology’s phenomenal repeat business rate.     Notably, within the last two years, Jeff successfully created and implemented ACT Oncology’s Project Management infrastructure, enhancing our use of standard processes and methodologies across studies and increasing the consistency of our operational performance.  The results of these efforts have been particularly noticeable in the conduct of several global programs involving CRO partners.   Jeff also developed ACT Oncology’s employee mentorship program, focused on training and developing key competencies to enhance career opportunities for our employees.

In his new role, in addition to overseeing the Project Management Function, Jeff will be responsible for managing the execution and delivery of all clinical trials to ensure the highest quality service to ACT Oncology’s growing client base.  He will also oversee global governance for trials involving our European partners and will confirm resourcing for new Requests for Proposals and new project wins.     As part of the Corporate Committee, Jeff will have direct input into evaluating and setting strategic priorities and will help lead company growth initiatives, including global CRO partnerships.


What our Clients are saying....

“We are very appreciative of our collaboration with ACT for the MMRC IST trials and for CoMMpass.  Your input continues to be so very helpful  in our efforts to clear hurdles and keep  building on the strong momentum we have created together. "

Beverly Harrison

Vice President, Clinical Development

Multiple Myeloma Research Foundation (MMRF)


“I also  appreciate the opportunity to recognize the most critical dimensions of strategic planning, as well as, operational excellence ACT brings to bear on our priority programs.   You and your team are very valued partners and critical to enabling us to meet not only our objectives, but also set new standards/models.”

Walter Capone

Chief Operating Officer

Multiple Myeloma Research Foundation (MMRF)


"The success of my company’s initial collaboration with ACT Oncology has led us to select them as our CRO for a number of subsequent programs.  We find that ACT Oncology’s management and operational staff share Onconova’s high performance standards and commitment to the development of new oncology treatments.  I view them as a true strategic partner and appreciate their ability to incorporate my feedback and requests into their resource planning."

Dennis Earle

Vice President, Clinical Operations

Onconova Therapeutics, Inc.





We're changing our name and website to reflect our exciting new capabilities since joining Precision for Medicine. Please visit us at to see how we’re delivering the next generation of CRO services for oncology innovators.